Rare diseases
Investigational molecules
Locations
Glutamic acid is a non-essential amino acid that occurs naturally in the body in its L-form. According to DrugCentral, it is the most common excitatory neurotransmitter in the central nervous system.[2] It is also known by several other names, including glutamate, L-glutamic acid, glutaminic acid, and glutaminol.[2]
In the EU Clinical Trials Information System, glutamic acid appears as one component of a fixed combination product used in a clinical trial. The product record lists glutamic acid together with other amino acids such as valine, arginine, alanine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, aspartic acid, glycine, histidine, and tryptophan, as well as electrolytes and glucose.[1] The product is authorised as a medicine, and glutamic acid serves as the test substance in one trial.[1]
Glutamic acid functions as an excitatory neurotransmitter in the central nervous system, meaning it helps transmit signals between nerve cells.[2] As an amino acid, it is also a building block for proteins in the body. In the context of the LOTUS trial, glutamic acid is part of an intradialytic parenteral nutrition combination intended to supply amino acids and other nutrients directly into the bloodstream during hemodialysis sessions. The trial aims to study whether this nutritional support can influence muscle protein synthesis in patients undergoing chronic hemodialysis.[1]
The therapeutic area of the trial is classified under nutritional and metabolic diseases.[1]
In the LOTUS trial, glutamic acid is given as part of a fixed combination product administered by the parenteral route, meaning it is delivered directly into the body bypassing the digestive system, for example by infusion into a vein.[1] The product is described as an intradialytic parenteral nutrition product, which means it is given during dialysis sessions.[1] The combination includes amino acids, electrolytes, and glucose monohydrate.[1]
One clinical trial in the EU Clinical Trials Information System investigates glutamic acid as part of a combination product. The LOTUS trial is a Phase 3 interventional study that is currently authorised and plans to enrol 20 participants.[1]
The trial enrols patients with chronic hemodialysis and studies muscle protein turnover. The primary outcome measure is the difference in myofibrillar fractional synthetic rate — a measure of how quickly muscle proteins are being built — during a one-week treatment with intradialytic parenteral nutrition compared with a control.[1] The trial also aims to characterise the hemodynamic effects of the intradialytic parenteral nutrition, meaning its effects on blood flow and blood pressure.[1]
The supplementary source provided does not describe specific side effects for glutamic acid. No side effect information is therefore reported on this page.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
